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Post-Reperfusion Myocardial Infarction
ong-Term Survival Improvement
sing Adenosine Regulation With Acadesine
ennis T. Mangano, PHD, MD, Yinghui Miao, MD, MS, Iulia C. Tudor, PHD,
ynthia Dietzel, MD, for the Investigators of the Multicenter Study of Perioperative Ischemia (McSPI)
esearch Group and the Ischemia Research and Education Foundation (IREF)
an Bruno, California
OBJECTIVES The purpose of this study was to assess the safety and efficacy of the adenosine regulating
agent (ARA) acadesine for reducing long-term mortality among patients with post-
reperfusion myocardial infarction (MI).
BACKGROUND No prospectively applied therapy exists that improves long-term survival after MI associated
with coronary artery bypass graft (CABG) surgery—a robust model of ischemia/reperfusion
injury. Pretreatment with the purine nucleoside autocoid adenosine mitigates the extent of
post-ischemic reperfusion injury in animal models. Therefore, we questioned whether use of
the ARA acadesine—by increasing interstitial adenosine concentrations in ischemic tissue—
would improve long-term survival after post-reperfusion MI.
METHODS At 54 institutions, 2,698 patients undergoing CABG surgery were randomized to receive
placebo (n  1,346) or acadesine (n  1,352) by intravenous infusion (0.1 mg/kg/min; 7 h)
and in cardioplegia solution (placebo or acadesine; 5 g/ml). Myocardial infarction was
prospectively defined as: 1) new Q-wave and MB isoform of creatine kinase (CK-MB)
elevation (daily electrocardiography; 16 serial CK-MB measurements); or 2) autopsy
evidence. Vital status was assessed over 2 years, and outcomes were adjudicated centrally.
RESULTS Perioperative MI occurred in 100 patients (3.7%), conferring a 4.2-fold increase in 2-year
mortality (p  0.001) compared with those not suffering MI. Acadesine treatment, however,
reduced that mortality by 4.3-fold, from 27.8% (15 of 54; placebo) to 6.5% (3 of 46;
acadesine) (p  0.006), with the principal benefit occurring over the first 30 days after MI.
The acadesine benefit was similar among diverse subsets, and multivariable analysis confirmed
these findings.
CONCLUSIONS Acadesine is the first therapy proven to be effective for reducing the severity of acute
post-reperfusion MI, substantially reducing the risk of dying over the 2 years after
infarction. (J Am Coll Cardiol 2006;48:206–14) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.044Cardiology Foundation
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heperfusion injury, occurring with restoration of blood flow
o ischemic tissue, is associated with myocardial cell death
nd apoptosis, microvascular injury, myocardial stunning,
nd arrhythmias—all of which can result in mortality and
orbidity, including heart failure (1,2).
See page 215
eperfusion injury can occur after percutaneous coronary
ntervention (PCI) or thrombolysis for acute myocardial
nfarction (MI) as well as after coronary blood flow is halted
or 30 min or longer during coronary artery bypass graft
CABG) surgery. Over the past three decades, the adoption
f highly effective new pharmacological and mechanical
eperfusion treatments has improved survival for patients
ho experience acute MI. Adjunctive antiplatelet and anti-
From the Ischemia Research and Education Foundation (IREF), San Bruno,
alifornia. The in-hospital study (1024) had been funded by Gensia Pharmaceuticals,
ith any and all funding ending by 2000. The IREF provided all of the funding for
he long-term study, including data collection, central analysis, data disposition, and
anuscript preparation.p
Manuscript received February 7, 2006; revised manuscript received March 30,
006, accepted April 4, 2006.oagulation therapies have produced further improvements
n clinical outcomes for these patients (3–5). Although
everal techniques have shown promise in preclinical mod-
ls, no drug or technique has been shown to reduce
eperfusion injury in the medical or PCI treatment of acute
I.
In the controlled ischemia/reperfusion setting of coronary
evascularization bypass graft surgery, where the myocar-
ium must be made ischemic, an estimated 3% to 20% of
atients experience MI associated with reperfusion after
ypass grafting (6); however, no effective pretreatment to
revent or lessen the loss of viable myocardium has been
ffective.
One approach to reduce ischemia/reperfusion injury—
denosine regulation using acadesine—is particularly in-
riguing, given the fundamental role adenosine plays in
eperfusion, preconditioning, and inflammation, espe-
ially in light of the unique safety profile of this agent,
chieved through its site- and event-specific character.
herefore, we designed a long-term survival study with
he in-hospital, multi-institutional, randomized trial co-
ort of nearly 3,000 patients, prospectively assessing
ost-reperfusion MI, and following all patients over the 2
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July 4, 2006:206–14 Acadesine and Reperfusion MI Survivalears after surgery. We hypothesized that, assessed
gainst placebo, acadesine treatment improved 2-year
urvival among those patients suffering post-reperfusion
I.
ETHODS
n-hospital and long-term post-infarction survival study
esigns. The Acadesine 1024 Trial had assessed the effects
f acadesine versus placebo on MI and secondarily on the
ombined outcome of cardiac death, MI, or stroke assessed
t 4 days after CABG surgery. This in-hospital, multi-
nstitutional clinical trial was prospectively designed, ran-
omized, placebo-controlled, and double-blinded. For all
atients, institutional approval and patient informed con-
ent were obtained before enrollment. The study—designed
o detect a 50% or greater reduction in the primary end
oint—was stopped for futility, having shown a statistically
nsignificant 15% reduction with acadesine (22% adjusted
or early stopping) in perioperative MI. Regarding safety,
he number and incidence of serious adverse events was
imilar among groups: acadesine-treated patients experi-
nced 506 events, with a 16.9% incidence (n  228 of
,351), whereas those patients administered placebo had
47 events, with a 17.9% incidence (n 241 of 1,345) (p
.35). In addition, the types of serious adverse events were
imilar (Table 1). Additionally, the incidence of adverse
vents was not different between groups, (i.e., 93.6% [n 
,264 of 1,351] in the acadesine group, and 93.4% [n 
,256 of 1,345] in the placebo group [p  0.82]).
The current long-term follow-up study was prospectively
esigned to investigate the effects of acadesine versus pla-
able 1. Serious Adverse Events
Adverse Event
WHO Preferred Term)
Placebo
(n  1,345)
Acadesine
(n  1,351)
ardiac failure 54 (4.0) 35 (2.6)
nfection 35 (2.6) 32 (2.4)
espiratory insufficiency 27 (2.0) 32 (2.4)
eath 34 (2.5) 30 (2.2)
erebrovascular disorder 26 (1.9) 24 (1.8)
ypotension 23 (1.7) 20 (1.5)
trial fibrillation 24 (1.8) 19 (1.4)
ardiac arrest 16 (1.2) 17 (1.3)
emorrhage NOS 22 (1.6) 16 (1.2)
entricular tachycardia 13 (1.0) 16 (1.2)
neumonia 19 (1.4) 15 (1.1)
entricular fibrillation 21 (1.6) 11 (0.8)
Abbreviations and Acronyms
ARA  adenosine regulating agent
CABG  coronary artery bypass graft
CK-MB  MB isoform of creatine kinase
MI  myocardial infarction
PCI  percutaneous coronary interventiont
alues are n (%).
NOS  not otherwise specified; WHO  World Health Organization.ebo on 2-year, all-cause mortality after perioperative MI
as defined in the in-hospital study protocol described
erein) in the Acadesine 1024 Trial. After conclusion of the
n-hospital enrollment, we designed the current study and
hen collected long-term data.
tudy drug administration and protocol. Starting approx-
mately 15 min before induction of anesthesia, the study
rug (acadesine or placebo) was administered intravenously
t 0.1 mg/kg/min for 7 h continuously. Administration thus
ccurred during the intraoperative (pre- and post-bypass)
nd immediately postoperative (into the intensive care unit)
eriods. The trial was blinded to all clinicians, investigators,
nd analysis team members. In addition, if cardioplegia
olution was used for myocardial protection during cardio-
ulmonary bypass, it contained either acadesine at a con-
entration of 5 g/ml for patients randomized to receive
cadesine or sterile water for injection for patients random-
zed to receive placebo.
Preoperatively, cardiac history and cardiac catheterization
ndings were recorded by investigators. Cardiovascular
edications in use at the time of admission (including
itrates, beta-blocking and calcium channel-blocking drugs,
spirin) were continued until the time of surgery; however,
he use of agents potentially affecting endogenous adenosine
oncentration (which could complicate the analysis of effi-
acy) was restricted: allopurinol was discontinued, dipyri-
amole was to be discontinued at least 48 h before surgery
nd not resumed until 24 h after surgery; methylxanthines
ere to be restricted for the 24 h before and the 48 h after
urgery; and adenosine and pentoxifylline were to be re-
tricted 12 h before and for 48 h after surgery.
During surgery, patients were monitored without restric-
ion, according to the institution’s standard practice for
ardiovascular and pulmonary function. Heart rate and
lood pressure were to be maintained within specific bound-
ries with anesthetic alterations and cardiovascular agents
uring the pre-bypass, bypass, and post-bypass periods. For
ll studies, prophylactic use of cardiovascular agents having
otential anti-ischemic properties (nitrates, calcium channel
lockers) was specifically excluded to avoid confounding
nterpretation of the data. Anesthetic techniques were
rescribed. Cardiopulmonary bypass procedure and surgical
echnique were determined by the individual surgeon. By-
ass typically was conducted with a membrane oxygenator
nd arterial filter with hemodilution and moderate systemic
ypothermia. Neither the type nor mode of administration
f cardioplegia was controlled. The use of inotropic and
asodilating agents was not controlled, but all medications
dministered were recorded.
easurement of outcomes. All outcomes were pre-
pecified, defined by protocol, and adjudicated by investi-
ators blinded to treatment group. Post-reperfusion MI was
efined prospectively by protocol. Myocardial infarction
equired either: 1) the presence of both a new Q-wave on
lectrocardiography and new post-reperfusion elevation of
he MB isoform of creatine kinase (CK-MB); or 2) evidence
o
e
o
e
b
C
o
d
r
T
f
c
c
c
C
r
5
a
T
p
fi
d
d
t
L
f
F
p
r
o
a
208 Mangano et al. JACC Vol. 48, No. 1, 2006
Acadesine and Reperfusion MI Survival July 4, 2006:206–14f infarction upon autopsy (7,8). For all patients, 12-lead
lectrocardiography data were collected daily, preoperatively
n the day of surgery and postoperatively through postop-
rative day 4. New Q waves were diagnosed by central,
linded investigators with Minnesota Code criteria. The
K-MB concentrations were sampled before surgery and
ver 16 time-periods (9) during the first 4 postoperative
ays and analyzed centrally by SmithKline Beecham labo-
atories, with an immunoenzymetric assay (Hybritech
andem-E CK-MB II, Hybritech Inc., San Diego, Cali-
ornia). The pre-specified CK-MB criteria for infarction (in
ombination with a new Q-wave) were: 1) CK-MB con-
entration 100 ng/ml anytime after removal of the aortic
igure 1. Consort diagram for the study patients. *Myocardial infarction
resence of a new Q-wave on electrocardiogram and new post-reperfusio
emoval of cross clamp, with a bordering value of 50% or more; or 70%
f 50% or more; or 70 ng/ml anytime after 36 h after removal of cross clamp)
rtery bypass graft; CPB  cardiopulmonary bypass.ross clamp, with a bordering value of 50% or more; 2)
K-MB concentration 70 ng/ml anytime after 12 h after
emoval of the aortic cross clamp with a bordering value of
0% or more; or 3) CK-MB concentration 70 ng/ml
nytime after 36 h after removal of the aortic cross clamp.
he presence of infarction at autopsy was based on autopsy
athologic data from the respective institution and con-
rmed centrally by the end point committee. An indepen-
ent safety and data monitoring panel reviewed all safety
ata on an ongoing basis and oversaw the stopping rules for
he trial.
ong-term survival assessment. The current long-term
ollow-up study was prospectively designed to investigate
indicates large, acute ST-segment elevation MI requiring either: 1) the
vation of the MB isoform of creatine kinase (100 ng/ml anytime after
l anytime after 12 h after removal of cross clamp with a bordering value(MI)
n ele
ng/m; or 2) the presence of autopsy evidence of infarction. CABG  coronary
t
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July 4, 2006:206–14 Acadesine and Reperfusion MI Survivalhe effects of acadesine versus placebo on 2-year all-cause
ortality after perioperative MI (as defined in the in-
ospital study protocol described herein) in the Acadesine
024 Trial. After conclusion of the in-hospital enrollment,
e designed the current study and then collected long-term
urvival data. Patients’ survival status at 2 years was deter-
ined by telephone interview, if possible; the U.S. National
able 2. Baseline Characteristics for All Patients, Patients Sufferi
All Patients
Placebo
(n  1,345)
Acadesine
(n  1,350)
p
Value
ge
Mean  SD 63.2  9.5 63.1  9.6
Median 64.0 64.0 0.58
ender: female 286 (21.3) 254 (18.8) 0.11
edical history
Smoking 986 (73.6) 966 (71.7) 0.28
Myocardial infarct(s) 716 (53.8) 725 (54.3) 0.81
Angina 1,269 (94.3) 1,273 (94.3) 0.95
Arrhythmias 234 (17.5) 234 (17.4) 0.96
Congestive heart failure 182 (13.5) 169 (12.5) 0.43
Hypercholesterolemia 693 (54.7) 722 (56.1) 0.48
Hypertension 796 (59.5) 773 (57.5) 0.30
Valvular disease 85 (6.32) 80 (5.94) 0.68
CABG 108 (8.03) 95 (7.04) 0.33
PTCA 172 (12.8) 184 (13.6) 0.52
Diabetes 350 (26.0) 351 (26.0) 0.99
Stroke 115 (8.55) 102 (7.56) 0.34
Neurologic disease 286 (21.3) 292 (21.6) 0.82
Vascular disease 418 (31.1) 384 (28.4) 0.13
reoperative medications
Aspirin use
(prior to surgery)
358 (26.6) 359 (26.6) 0.99
Beta-blockers use
(prior to surgery)
765 (56.9) 774 (57.3) 0.81
Calcium channel
blockers use
(prior to surgery)
802 (59.6) 776 (57.5) 0.26
Lipid-lowering agents use
(prior to surgery)
239 (17.8) 254 (18.8) 0.48
alues are n (%) unless indicated otherwise.
CABG  coronary artery bypass grafting; MI  myocardial infarction; PTCA igure 2. Kaplan-Meier analysis of 2-year survival according to with or withouteath Index; Medicare claims data; or Canadian provincial
eath indices and registries.
ata and statistical analyses. Among patients suffering a
ost-reperfusion MI, the risk of all-cause death at 2 years
or patients randomized to acadesine versus placebo
primary hypothesis) was compared with the chi-square
est and adjusted sequential analysis. Odds ratios and
I, and Patients Not Suffering MI
Patients With MI Patients Without MI
cebo
54)
Acadesine
(n  46)
p
Value
Placebo
(n  1,291)
Acadesine
(n  1,304)
p
Value
 8.9 62.0  10.1 63.2  9.6 63.1  9.5
5.0 63.5 0.45 64.0 64.0 0.67
27.8) 12 (26.1) 0.85 271 (21.0) 242 (18.6) 0.12
66.7) 35 (76.1) 0.30 950 (73.9) 931 (71.6) 0.19
64.2) 30 (65.2) 0.91 682 (53.4) 695 (53.9) 0.80
96.3) 44 (95.7) 0.99 1,217 (94.3) 1,229 (94.2) 0.98
22.2) 4 (8.70) 0.07 222 (17.3) 230 (17.7) 0.77
14.8) 5 (10.9) 0.56 174 (13.5) 164 (12.6) 0.50
66.0) 27 (61.4) 0.64 660 (54.2) 695 (55.9) 0.40
66.7) 24 (53.3) 0.18 760 (59.2) 749 (57.7) 0.43
7.41) 2 (4.35) 0.68 81 (6.28) 78 (6.00) 0.76
24.1) 5 (10.9) 0.09 95 (7.36) 90 (6.90) 0.65
11.1) 7 (15.2) 0.54 166 (12.9) 177 (13.6) 0.59
24.1) 8 (17.4) 0.41 337 (26.1) 343 (26.3) 0.91
11.1) 5 (10.9) 0.97 109 (8.44) 97 (7.44) 0.34
25.9) 13 (28.3) 0.79 272 (21.1) 279 (21.4) 0.84
27.8) 12 (26.1) 0.85 403 (31.2) 372 (28.5) 0.13
16.7) 8 (17.4) 0.92 349 (27.0) 351 (26.9) 0.95
61.1) 31 (67.4) 0.51 732 (56.7) 743 (57.0) 0.89
57.4) 25 (54.3) 0.76 771 (59.7) 751 (57.6) 0.27
22.2) 9 (19.6) 0.75 227 (17.6) 245 (18.8) 0.43
utaneous transluminal coronary angioplasty.ng M
Pla
(n 
63.4
6
15 (
36 (
34 (
52 (
12 (
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12 (postoperative myocardial infarction (MI) among the 2,698 study patients.
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Acadesine and Reperfusion MI Survival July 4, 2006:206–14heir 95% confidence intervals are presented with associ-
ted p values. For the survival data analyses, the Kaplan-
eier product-limit method was used to compare the
wo (acadesine vs. placebo) survival distributions. Sec-
ndarily, we performed multivariate analyses to confirm
he point-estimate and survival findings. Predictor vari-
bles significant at two-tailed nominal p values 0.2 in
nivariate analyses were entered into two multivariable
ogistic models for 2-year mortality (acadesine- and
lacebo-treated patients). Stepwise logistic regression
as performed, retaining variables significant at two-
ailed nominal p values 0.05. The occurrence of MI
hen was forced into both models to assess differential
ffects. Two approaches were taken. In the first, we
erformed logistic regression within the placebo popula-
ion, assessing perioperative factors, including post-
eperfusion MI, for association with 2-year mortality, and
n parallel, performed the same analysis for acadesine
atients. In the second, we performed logistic regression
or all patients, testing the interaction between treatment
nd MI for 2-year mortality. All statistical analyses were
erformed with SAS version 8.12 software (SAS Insti-
ute, Cary, North Carolina).igure 3. (A) Kaplan-Meier analysis of 2-year survival according to the use
ost-reperfusion myocardial infarction (MI). (B) Two-year mortality by-MI anESULTS
total of 2,698 patients were randomized. Three patients
ad incomplete data, leaving 1,345 receiving placebo and
,350 receiving acadesine, or a total of 2,695 patients (Fig.
). Generally, for all patients and for patients with and
ithout postoperative MI, placebo- and acadesine-treated
atients had similar cardiac medical histories and preoper-
tive medications (Table 2); furthermore, the groups were
imilar for preoperative cardiac catheterization findings,
ardioplegia types, and mean durations of placebo and
cadesine infusions (see subsequent section regarding
ABG incidence difference for patients with versus without
I).
ost-reperfusion MI. Myocardial infarction occurred in
00 of the 2,695 patients enrolled (3.7%). Although
cadesine reduced the incidence of MI (placebo, 4.01% [54
f 1,345]; acadesine, 3.41% [46 of 1,350]), the reduction
as not statistically significant (p  0.24).
ost-reperfusion MI, long-term survival, and treatment.
he occurrence of a perioperative MI conferred a 4.2-fold
ncreased risk in 2-year mortality. Among the 2,595 patients
ot suffering infarction, 2-year mortality was 4.28%, versusor non-use of acadesine among the 100 study patients who sustained
d by-treatment.
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July 4, 2006:206–14 Acadesine and Reperfusion MI Survival8.0% among the 100 patients suffering infarction (p 
.001). The primary mortality effect appeared over the first
0 days after infarction (Fig. 2). Nine placebo-treated
atients had MI diagnosed at autopsy versus one acadesine-
reated patient.
The impact of acadesine treatment on post-infarction
urvival was significant. Acadesine treatment was associated
ith a 4.3-fold reduction in 2-year mortality from 27.78%
15 of 54; placebo) to 6.52% (3 of 46; acadesine) (p 0.006)
ith the principal benefit occurring over the first 30 days
fter MI (Figs. 3A and 3B).
The acadesine benefit was similar among diverse subsets,
ncluding gender, race, age, disease acuity, and insurance-
ype (Fig. 4).
ultivariable analyses for long-term survival. Multivari-
ble analyses for the placebo-treated patients (Table 3)
emonstrated the independent effect of MI on 2-year
ortality, whereas the occurrence of MI in acadesine-
reated patients (Table 4) annulled the effect of post-
eperfusion MI on mortality. The interaction between
reatment and MI for 2-year mortality was sustained over
igure 4. Two-year mortality: acadesine versus placebo by patient characte
ypass graft; CCB  calcium channel blocker; CHF  congestive heart fai
myocardial infarction; PTCA  percutaneous transluminal coronary an
able 3. Results of Multivariable Logistic Regression for
-Year Mortality Among the Placebo-Treated Patients
Risk Factor
Odds Ratio
(95% CI)
p
Value
revious CABG surgery 2.61 (1.29–5.28) 0.008
edical history of congestive
heart failure
2.96 (1.62–5.41) 0.001
edical history of
hypercholesterolemia
0.56 (0.32–0.97) 0.04
edical history of vascular
disease
2.60 (1.49–4.52) 0.001
spirin use after reperfusion 0.52 (0.29–0.92) 0.02
ost-reperfusion stroke 8.11 (2.88–22.86) 0.001
ost-reperfusion MI 12.38 (5.82–26.34) 0.001tI  confidence interval; other abbreviations as in Table 2.he entire population and was independent of other periop-
rative covariates, including prior CABG (Table 5). His-
orical and perioperative factors that were independently
ssociated with mortality were not unexpected, nor was the
imilarity between covariates for the placebo-patient analy-
is (Table 3) versus the acadesine-patient analysis (Table 4).
ost impressive was the effectiveness of acadesine in
educing the placebo-MI odds from 12.4 (p 0.001) to 0.8
p  0.69).
ISCUSSION
he objective of the current study was to assess the effects of
ost-reperfusion MI on 2-year survival and, if substantial, to
etermine whether treatment with acadesine mitigates those
ffects compared with placebo (that is, improves 2-year
urvival after post-reperfusion MI). With the Acadesine
024 Trial—which involved 54 centers and 2,695 patients
ith complete data—our prospectively designed, long-term
tudy found that post-reperfusion MI conferred a four-fold
ncreased risk of long-term mortality. Importantly,
cadesine treatment was associated with a four-fold reduc-
ion in 2-year mortality after perioperative post-reperfusion,
cute MI. Both of these findings were statistically signifi-
ant. Additionally, the primary point-estimate end point
ndings of this trial were cross-validated with several
ultivariable analyses that clearly indicated that for
lacebo-treated patients, post-reperfusion MI was associ-
ted with substantial risk for death over the 2 years after
urgery (Table 3); however, that substantial risk was entirely
nnulled by treatment with acadesine (Table 4). The critical
nteraction between treatment and MI for 2-year mortality
roved highly significant and independent of other promi-
ent covariates, including prior CABG; differences between
cadesine-MI and placebo-MI groups proved inconsequen-
ASA  acetylsalicylic acid; BB  beta-blocker; CABG  coronary artery
YS  dysrhythmia; HX  history of; LLA  lipid-lowering agents; MI
asty; UA  unstable angina.ristic.ial (Table 5). Given our prior meta-analysis findings
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Acadesine and Reperfusion MI Survival July 4, 2006:206–14ndicating a statistically significant short-term cardioprotec-
ive effect of acadesine (7), the present results indicate that
he immediate benefit of acadesine is sustained for 2 years.
t is the first trial of this size to demonstrate an important
eduction in mortality associated with reperfusion-induced
I in any setting of clinical revascularization and the first to
how a sustained benefit over the long term.
Numerous studies evaluating the use of pharmacologic
nd mechanical therapies to mitigate reperfusion injury have
roven unsuccessful not only in CABG surgery but in PCI
s well. These approaches have focused on oxygen free
adicals (9,10), neutrophil accumulation and activation
8,11), intracellular Ca2 overload via sodium-hydrogen
xchange (NHE) inhibition (12,13), complement activation
14–16), hypothermia (17,18), hyperbaric oxygenation
19,20), and distal embolic protection devices (21). In each
f these approaches, specific mechanisms of reperfusion
njury were targeted. Their disappointing results might
eflect the inherent limitations of therapies that target
pecific mechanisms or cell types involved in the pathophys-
ology of reperfusion injury, perhaps because they fail to
ddress the full spectrum of its complexity.
Table 4. Results of Multivariable Logistic Reg
Acadesine-Treated Patients
Risk Factor
Age  65 yrs
Medical history of hypercholesterolemia
Medical history of stroke
Medical history of vascular disease
Return to CPB
Aspirin use after reperfusion
Inotropes/vasoconstrictors use on remaining day of r
Post-reperfusion stroke
Post-reperfusion renal failure
Post-reperfusion MI
CPB  cardiopulmonary bypass; other abbreviations as in T
Table 5. Results of Multivariable Logistic Reg
Risk Factor
Age  65 yrs
Female gender
Medical history of angina
Medical history of congestive heart failure
Medical history of hypercholesterolemia
Medical history of vascular disease
Previous CABG surgery
Inotrope* use on remaining day of reperfusion
Post-reperfusion renal failure
Post-reperfusion stroke
Aspirin use (post surgery)
Post-reperfusion MI vs. no MI: placebo-treated pati
Post-reperfusion MI vs. no MI: acadesine-treated pa
Acadesine vs. placebo: patients with post-reperfusion
Acadesine vs. placebo: patients without post-reperfus*Inotrope: epinephrine, norepinephrine, amrinone, milrinone, and
Abbreviations as in Tables 2 and 3.Adenosine targets a broader spectrum of the pathophys-
ology of ischemia/reperfusion injury. It has been shown to
mprove post-ischemic ventricular function and reduce neu-
rophil accumulation and activation and myocardial necrosis
nd apoptosis (22). Adenosine directly inhibits neutrophil
unction. Most importantly, adenosine has been shown to
e a powerful inducer of ischemic preconditioning (24).
reconditioning has offered the most potent approach to
educing infarct size in ischemia/reperfusion animal models.
major mechanism for this effect appears to be the
eduction of post-reperfusion apoptosis of myocytes (23).
he current results support this mechanism of action in
uman subjects. The iatrogenic ischemia of coronary bypass
s a well-controlled ischemia/reperfusion event in man. The
pparent reduction in post-MI mortality suggests a precon-
itioning mechanism to decrease infarct size. Thus, presum-
bly smaller infarctions in ARA-treated patients resulted in
ower mortality. This finding was confirmed by the multi-
ariable logistic regression for the two groups.
Systemic adenosine has been most recently studied in the
MISTAD-II (Acute Myocardial Infarction Study of
denosine-II) trial, which set out to determine the effect of
n for 2-Year Mortality Among the
Odds Ratio
(95% CI)
p
Value
3.22 (1.69–6.14) 0.001
0.48 (0.26–0.86) 0.01
2.46 (1.18–5.15) 0.02
3.02 (1.69–5.42) 0.001
2.78 (1.19–6.51) 0.02
0.47 (0.25–0.87) 0.02
sion 2.51 (1.37–4.58) 0.003
10.6 (3.64–30.9) 0.001
4.54 (1.40–14.76) 0.01
0.76 (0.19–2.99) 0.69
2 and 3.
n for 2-Year Mortality Among All Patients
Odds Ratio
(95% CI)
p
Value
2.12 (1.40–3.23) 0.001
1.64 (1.05–2.57) 0.03
0.44 (0.22–0.91) 0.03
1.98 (1.25–3.13) 0.003
0.52 (0.34–0.78) 0.002
2.81 (1.88–4.20) 0.001
2.45 (1.41–4.27) 0.002
2.43 (1.62–3.64) 0.001
3.18 (1.38–7.35) 0.007
8.48 (4.04–17.78) 0.001
0.51 (0.33–0.77) 0.002
11.92 (5.48–25.95) 0.001
0.95 (0.26–3.52) 0.94
0.10 (0.02–0.41) 0.002
I 1.21 (0.79–1.83) 0.38ressio
eperfuressio
ents
tients
MI
ion Menoximone.
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July 4, 2006:206–14 Acadesine and Reperfusion MI Survivalntravenous adenosine on clinical outcomes and infarct size
n ST-segment elevation MI patients (25). Although aden-
sine did not show an overall reduction in adverse clinical
vents in the primary end point (death or heart failure), the
reated arm did demonstrate a positive trend toward a
maller median infarct size; however, in this setting of
denosine administration well after onset of ischemia, myo-
ardial concentration would be predicted to be much lower
han with ARAs, owing to the very short intravascular
alf-life of adenosine (1 s). The trend toward smaller
nfarct size is consistent with results seen in the
MISTAD-I trial as well as in a small study on intracoro-
ary administration of adenosine in patients undergoing
ngioplasty (26,27). Clinical utility of systemic adenosine,
owever, is limited, owing to adenosine’s undesirable pe-
ipheral hemodynamic side effects.
tudy limitations. We believe the current study’s method-
logy was robust (including prospectively defined hypothe-
es, data collection and analysis, all executed before unblind-
ng). This study was a scientific product of the Ischemia
esearch and Education Foundation (IREF), which re-
eived no support for the long-term study. Yet, an inherent
ias exists. In 2000, the primary investigator (D.T.M.) was
ranted a sublicense to the intellectual property rights of
cadesine (from the University of California and Metabasis
herapeutics, San Diego, California), and he continues to
old such license. Nonetheless, the prospective nature of the
esign and analyses was designed to eliminate any effect of
uch conflict on the methods, analyses, and results of the
urrent study (see the Methods and Results sections).
econd, measures of infarct size would have allowed insight
nto mechanisms for acadesine’s beneficial long-term effects
n mortality, but such assessment was not straightforward
ere. For example, in 10 placebo patients versus 1 acadesine
atient, death occurred very early after MI (which itself
ight indicate an effect on “MI size”); however, few of these
ery early deaths had sufficient cardiac enzyme measure-
ents to allow accurate estimation of MI size (e.g., area-
nder-the-curve of CK-MB or troponin concentration)—
hat is, for the most serious MIs (those that resulted in early
eath), sizing of MI could not be accomplished. Finally, we
ave noted a difference among MI patients for history of
ABG surgery; however, this difference proven in multiple
nalyses does not confound the findings.
onclusions. Our results support the hypothesis that the
herapeutic approach of safely increasing endogenous aden-
sine at the site of ischemia enables reduction of reperfusion
njury and post-infarction mortality. Acadesine represents
he prototype of a new class of ARAs that substantially
ncrease endogenous adenosine, but importantly, only in
schemic tissue and only under conditions of adenosine
riphosphate catabolism, imparting a unique safety profile
bserved in this study. Preventative treatment with
cadesine is safe and useful for reduction of long-term
ortality among patients suffering post-reperfusion, peri-
perative MI. Additional studies will be required to deter-ine the usefulness of acadesine or other ARAs in other
ettings of ischemia/reperfusion injury.
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